- Investing Ideas
- Swiss Pharmaceuticals & Biotech Large Cap High Growth Potential
Swiss Pharmaceuticals & Biotech Large Cap High Growth Potential
Results
4
Large Cap Companies that analysts expect to have high earnings, revenue or cash flow growth in the next 3 years.
4 companies
Novartis
Market Cap: CHF 229.8b
Researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally.
NOVN
CHF 125.54
7D
2.5%
1Y
36.2%
Galderma Group
Market Cap: CHF 41.0b
Operates as a dermatology company worldwide.
GALD
CHF 175.00
7D
3.7%
1Y
42.0%
Sandoz Group
Market Cap: CHF 28.8b
Develops, manufactures, and markets generic and biosimilars worldwide.
SDZ
CHF 66.54
7D
2.1%
1Y
43.5%
Lonza Group
Market Cap: CHF 39.4b
Operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally.
LONN
CHF 564.00
7D
-3.2%
1Y
1.6%